New drug duo targets 'Undruggable' lung cancer mutation in First-Line trial
NCT ID NCT07198841
Summary
This study is testing whether a new combination of two drugs (IBI351 and cetuximab β) can help control advanced lung cancer in people who have not yet received treatment and have a specific genetic change called KRAS G12C. The trial will enroll 48 adults to see how well the tumors shrink and how long the treatment keeps the cancer from growing. The main goal is to measure the response rate to this first-line therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Tumor Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First People's Hospital of Foshan
RECRUITINGFoshan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Fourth Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The first affiliated hospital of nanchang university
RECRUITINGNanchang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.